(PDF) Assessing the Activity of Cediranib, a VEGFR-2/3

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, Against VEGFR-1 and Members of the Structurally Related PDGFR Family

Molecular Cancer Therapeutics - United States

doi 10.1158/1535-7163.mct-10-0976

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

March 25, 2011

Authors

C. L. Farnsworth

J. M. Jurgensmeier

Publisher

American Association for Cancer Research (AACR)

Related search

Analysis of Biological Effects and Signaling Properties of FLT-1 (VEGFR-1) and KDR (VEGFR-2)

Journal of Biological Chemistry

Molecular Biology

English

A Case Report of Successful Treatment of Metastatic Gastral Neuroendocrine Carcinoma to a Small-Molecule VEGFR-2 Tyrosine Kinase Inhibitor Apatinib

Biomedical Research

English

Inhibitor of DNA Binding 1 (ID1); VEGF Receptor 2 (KDR/Flk-1; VEGFR-2)

Science-Business eXchange

English

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research

Cancer Research

English

Generation and Characterization of a Human Nanobody Against VEGFR-2

Acta Pharmacologica Sinica

English

Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells

Cancer Research

English

Combined Blockade of VEGFR-2 and VEGFR-3 Inhibits Inflammatory Lymphangiogenesis in Early and Middle Stages

Investigative Ophthalmology and Visual Science

Molecular Neuroscience

Sensory Systems

English

Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants

Journal of Nuclear Medicine

Nuclear Medicine

English

Rapamycin Suppresses Angiogenesis and Lymphangiogenesis in Melanoma by Downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 Expression

OncoTargets and Therapy

English